NDA 010596 · Parke Davis
Celontin
Methsuximide · Oral · Anti-epileptic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 15, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1957
Feb 8, 1957
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
182
107 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
INDICATIONS AND USAGE Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 8, 1957 Original approval · Type 1 - New Molecular Entity · priority review Medication Guide
2 products under this application
- CELONTIN · METHSUXIMIDE 150MG · CAPSULE, ORAL · Discontinued
- CELONTIN · METHSUXIMIDE 300MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Methsuximide" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective25
- seizure21
- convulsion14
- dizziness13
- somnolence13
- feeling abnormal11
- generalised tonic-clonic seizure11
- off label use11
- fall9
- asthenia8
- drug interaction8
- fatigue8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 13 |
| 2016 | 10 |
| 2017 | 7 |
| 2018 | 21 |
| 2019 | 15 |
| 2020 | 15 |
| 2021 | 14 |
| 2022 | 14 |
| 2023 | 6 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Celontin (Methsuximide)
2024 spending
$249K
Beneficiaries
110
587 claims
Per beneficiary
$2,260
$4.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,186,246 |
| 2021 | $1,007,695 |
| 2022 | $885,860 |
| 2023 | $695,875 |
| 2024 | $248,624 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood.
Sigler M, Strassburg HM, Boenigk HE · Seizure 2001 · Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.